However, the trial was halted on September 18, 2023, due to a business decision.[27, 135] Agents including TD‐522, E14, FD‐001 and AG‐6033, mainly degrade GSPT1, but also reduce the level of IKZF1/3 slightly.[136, 137, 138, 139] Phase I clinical trials of FD‐001, a GSPT1/IKZF1/3 degrader, in recurrent/refractory hematologic malignancies, including AML, MDS, NHL, and MM (NCT06731699) were initiated in November 2023 in China. Here, GSPT1 is linked to Miyoshi myopathy.